Newborn bloodspot screening in the time of COVID-19.
Genet Med
; 23(6): 1143-1150, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1028696
ABSTRACT
PURPOSE:
A COVID-19 pandemic business continuity plan (BCP) was rapidly developed to protect the Victorian newborn screening (NBS) program. Here, we present the outcomes of our COVID-19 BCP and its impact on the Victorian NBS laboratory service.METHODS:
Change management principles were used to develop a BCP that included mapping of NBS processes against staff resources, triaging priorities, technology solutions, supply chain continuity, gap analysis, and supporting maternity service providers. The effect was assessed quantitatively by review of key performance indicator data and qualitatively from staff feedback.RESULTS:
A four-stage BCP was implemented. Stage 1 split teams into two, which rotated weekly, onsite (laboratory) and offsite (home). At 20 weeks post-implementation the BCP only progressed to stage 1 and the overall turnaround time was maintained. Staff experience indicated benefits from the review of workflow but noted some social impact associated with the change.CONCLUSION:
The preparedness and agility of implementation was based on our focus on the newborn babies and their families, our production system, and a continuous improvement mindset. Both our people and technology infrastructure processes are crucial to this success as we continue to adapt to new challenges.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Tamizaje Neonatal
/
COVID-19
Tipo de estudio:
Investigación cualitativa
Límite:
Femenino
/
Humanos
/
Recién Nacido
/
Embarazo
Idioma:
Inglés
Revista:
Genet Med
Asunto de la revista:
Genética Médica
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
S41436-020-01086-6
Similares
MEDLINE
...
LILACS
LIS